Affiliation:
1. Institute of Hygiene and Medical Microbiology Medical University of Innsbruck Innsbruck Austria
Abstract
AbstractThe COVID‐19 pandemic illustrated an urgent need for sophisticated, human tissue models to rapidly test and develop effective treatment options against this newly emerging severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Thus, in particular, the last 3 years faced an extensive boost in respiratory and pulmonary model development. Nowadays, 3D models, organoids and lung‐on‐chip, respiratory models in perfusion, or precision‐cut lung slices are used to study complex research questions in human primary cells. These models provide physiologically relevant systems for studying SARS‐CoV‐2 and, of course, other respiratory pathogens, but they are, too, suited for studying lung pathologies, such as CF, chronic obstructive pulmonary disease, or asthma, in more detail in terms of viral infection. With these models, the cornerstone has been laid for further advancing the organs by, for example, inclusion of several immune cell types or humoral immune components, combination with other organs in microfluidic organ‐on‐chip devices, standardization and harmonization of the devices for reliable and reproducible drug and vaccine testing in high throughput.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献